Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
Holding DVAX?
Track your performance easily
DVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.74 - $14.30
Previous CloseN/A
Volume272.71K
Average Volume (3M)1.59M
Market Cap
$1.63B
Enterprise Value$1.22B
Total Cash (Recent Filing)$81.42M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)95.1
Beta0.55
Next Earnings
Feb 20, 2025EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding131,454,560
10 Day Avg. Volume1,959,784
30 Day Avg. Volume1,585,768
Standard Deviation0.22
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.29
Price to Cash Flow (P/CF)21.10
P/FCF Ratio21.30
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue4.66
Enterprise Value/Gross Profit6.67
Enterprise Value/Ebitda30.89
Forecast
1Y Price Target
$28.33Price Target Upside128.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Dynavax News
PremiumCompany Announcements
Dynavax Reports Revenue Growth and Defense Contract
PremiumCompany Announcements
Dynavax Technologies Reports Strong Q3 2024 Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHeplisav-B sales increased by 27% year-over-year, showcasing strong growth in the company's marketed Hepatitis B vaccine.
Market OpportunityThe expanded market opportunity for Hepatitis-B vaccination in the U.S. is anticipated to grow to $900 million, with Heplisav-B expected to achieve at least 60% market share.
Market PositionHeplisav-B is the only two-dose adult Hepatitis B vaccine available, providing a unique market position for Dynavax.
Bears Say
Product DevelopmentThe Tdap program was discontinued due to an undifferentiated profile.
Regulatory ChallengesThe FDA issued a Complete Response Letter due to insufficient data, impacting the sBLA for a four-dose Heplisav-B regimen for adults on hemodialysis.
Sales PerformanceHeplisav-B sales in 3Q24 did not meet the analyst's estimate and consensus, falling short of expectations.
---
Ownership Overview
0.37% Insiders
17.34% Mutual Funds
0.07% Other Institutional Investors
57.87% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.74 and its highest was $14.30 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Dynavax Technologies Corp.’s market cap is $1.63B.
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is Feb 20, 2025 which is in 33 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Nov 07, 2024. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.113 by $0.007.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is 0.04.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 131,454,560 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.12 in its last earnings report, beating expectations of $0.113. Following the earnings report the stock price went up 8.236%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Currently, no hedge funds are holding shares in DVAX
---
Dynavax Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.33 (128.65% Upside)
$28.33 (128.65% Upside)
Blogger Sentiment
Bullish
DVAX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 320.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.62%
12-Months-Change
Fundamentals
Return on Equity
3.18%
Trailing 12-Months
Asset Growth
9.15%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
---
DVAX Company Deck
---
DVAX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, record sales of HEPLISAV-B, and strategic initiatives like the share repurchase plan. However, there were notable challenges with the discontinuation of the Tdap program and FDA hurdles. Overall, the sentiment leans positive due to the financial achievements and future growth prospects.Read More>---
DVAX Stock 12 Month Forecast
Average Price Target
$28.33
▲(128.65% Upside)
Technical Analysis
Insmed
―
ANI Pharmaceuticals
―
Verastem
―
Kiniksa Pharmaceuticals
―
Heron Therapeutics
―
BioNTech SE
―
Best Analysts Covering DVAX
1 Year
1 Year Success Rate
12/26 ratings generated profit
1 Year Average Return
-1.10%
reiterated a buy rating 4 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -1.10% per trade.
---